Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 702

1.

Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis.

Naito Y, Tamiya A, Tamiya M, Kimura Y, Hamaguchi M, Saijo N, Kanazu M, Tokura S, Shiroyama T, Morisita N, Omachi N, Suzuki H, Okamoto N, Okishio K, Hirashima T, Atagi S.

Medicine (Baltimore). 2017 Sep;96(35):e7884. doi: 10.1097/MD.0000000000007884.

2.

Combination of virtual bronchoscopic navigation, endobronchial ultrasound, and rapid on-site evaluation for diagnosing small peripheral pulmonary lesions: a prospective phase II study.

Maekura T, Sugimoto C, Tamiya A, Saijo N, Naoki Y, Koba T, Kimura Y, Matsuda Y, Kanazu M, Takeuchi N, Sasaki Y, Naito Y, Tsuji T, Sugawara R, Kobayashi T, Nakao K, Taniguchi Y, Okishio K, Omachi N, Kasai T, Atagi S.

J Thorac Dis. 2017 Jul;9(7):1930-1936. doi: 10.21037/jtd.2017.06.85.

3.

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.

Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Rukazenkov Y, Fukuoka M.

Lung Cancer. 2017 Feb;104:119-125. doi: 10.1016/j.lungcan.2016.11.022. Epub 2016 Nov 30.

4.

Highlights for ESMO 40: celebration review for lifetime achievement awards.

Saijo N.

ESMO Open. 2016 Feb 17;1(1):e000010. eCollection 2016. Review. No abstract available.

5.

Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma.

Nagai T, Arao T, Nishio K, Matsumoto K, Hagiwara S, Sakurai T, Minami Y, Ida H, Ueshima K, Nishida N, Sakai K, Saijo N, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Haji S, Kudo M.

Dig Dis. 2016;34(6):702-707. Epub 2016 Oct 17.

PMID:
27750241
6.

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.

Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ.

J Thorac Oncol. 2015 Jul;10(7):1099-106. doi: 10.1097/JTO.0000000000000548.

7.

Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.

Tamiya A, Tamiya M, Shiroyama T, Saijo N, Nakatani T, Minomo S, Tsuji T, Takeuchi N, Omachi N, Kurata K, Suzuki H, Okamoto N, Okishio K, Hirashima T, Atagi S.

Med Oncol. 2015 Mar;32(3):40. doi: 10.1007/s12032-014-0474-x. Epub 2015 Jan 25.

PMID:
25616723
8.

Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.

Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose Y, Okamoto H, Yamamoto N, Yoshioka H, Minato K, Sawa T, Iwamoto Y, Saka H, Mizusawa J, Shibata T, Nakamura S, Ando M, Yokoyama A, Nakagawa K, Saijo N, Tamura T.

J Clin Oncol. 2015 Feb 20;33(6):575-81. doi: 10.1200/JCO.2014.55.8627. Epub 2015 Jan 12.

PMID:
25584004
9.

Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207†.

Tsukada H, Yokoyama A, Goto K, Shinkai T, Harada M, Ando M, Shibata T, Ohe Y, Tamura T, Saijo N; Lung Cancer Study Group of the Japan Clinical Oncology Group (JCOG).

Jpn J Clin Oncol. 2015 Jan;45(1):88-95. doi: 10.1093/jjco/hyu176. Epub 2014 Nov 6.

PMID:
25378648
10.

Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.

Takahashi H, Sai K, Saito Y, Kaniwa N, Matsumura Y, Hamaguchi T, Shimada Y, Ohtsu A, Yoshino T, Doi T, Okuda H, Ichinohe R, Takahashi A, Doi A, Odaka Y, Okuyama M, Saijo N, Sawada J, Sakamoto H, Yoshida T.

PLoS One. 2014 Aug 15;9(8):e105160. doi: 10.1371/journal.pone.0105160. eCollection 2014.

11.

Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.

Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N.

J Clin Oncol. 2014 Apr 20;32(12):1262-8. doi: 10.1200/JCO.2013.53.5153. Epub 2014 Mar 17.

PMID:
24638015
12.

Distal promoter regions are responsible for differential regulation of human orosomucoid-1 and -2 gene expression and acute phase responses.

Sai K, Kurose K, Koizumi T, Katori N, Sawada J, Matsumura Y, Saijo N, Yamamoto N, Tamura T, Okuda H, Saito Y.

Biol Pharm Bull. 2014;37(1):164-8.

13.

Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).

Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS.

Lung Cancer. 2014 Feb;83(2):174-81. doi: 10.1016/j.lungcan.2013.11.021. Epub 2013 Dec 1.

14.

A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.

Sekine I, Okamoto H, Horai T, Nakagawa K, Ohmatsu H, Yokoyama A, Katakami N, Shibuya M, Saijo N, Fukuoka M.

Clin Lung Cancer. 2014 Mar;15(2):96-102. doi: 10.1016/j.cllc.2013.11.006. Epub 2013 Nov 14.

PMID:
24361248
15.

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.

Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S, Harada M, Okamoto H, Yamamoto N, Shinkai T, Sakai H, Matsui K, Nakagawa K, Shibata T, Saijo N, Tamura T; Japan Clinical Oncology Group.

Lancet Oncol. 2014 Jan;15(1):106-13. doi: 10.1016/S1470-2045(13)70511-4. Epub 2013 Dec 3.

PMID:
24309370
16.

KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study.

Watanabe T, Yoshino T, Uetake H, Yamazaki K, Ishiguro M, Kurokawa T, Saijo N, Ohashi Y, Sugihara K.

Jpn J Clin Oncol. 2013 Jul;43(7):706-12. doi: 10.1093/jjco/hyt062. Epub 2013 May 8.

PMID:
23657052
17.

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.

Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ, Rukazenkov Y.

Lung Cancer. 2013 Aug;81(2):280-7. doi: 10.1016/j.lungcan.2013.03.004. Epub 2013 Mar 26.

PMID:
23540718
18.

[Combination therapy of targeted drugs].

Saijo N.

Nihon Rinsho. 2012 Nov;70 Suppl 8:652-7. Japanese. No abstract available.

PMID:
23513917
19.

[History of cancer chemotherapy; from cytotoxic drugs to molecular targeted therapy].

Saijo N.

Nihon Rinsho. 2012 Nov;70 Suppl 8:18-23. Review. Japanese. No abstract available.

PMID:
23513805
20.

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials.

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Cancer Sci. 2013 Apr;104(4):481-5. doi: 10.1111/cas.12105. Epub 2013 Mar 15.

21.

[Present status and future prospects of antibody therapy against solid tumor].

Saijo N.

Nihon Rinsho. 2012 Dec;70(12):2051-7. Review. Japanese.

PMID:
23259374
22.

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.

Saijo N.

Yonsei Med J. 2013 Jan 1;54(1):1-14. doi: 10.3349/ymj.2013.54.1.1. Review.

23.

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.

Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP; meta-analysis of bevacizumab in advanced NSCLC collaborative group.

Ann Oncol. 2013 Jan;24(1):20-30. doi: 10.1093/annonc/mds590. Epub 2012 Nov 23. Review. Erratum in: Ann Oncol. 2013 Apr;24(4):1133.

PMID:
23180113
24.

Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant.

Tada M, Ishii-Watabe A, Maekawa K, Fukushima-Uesaka H, Kurose K, Suzuki T, Kaniwa N, Sawada J, Kawasaki N, Nakajima TE, Kato K, Yamada Y, Shimada Y, Yoshida T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Okuda H, Hamaguchi T, Saito Y, Matsumura Y.

Immunogenetics. 2012 Dec;64(12):869-77. doi: 10.1007/s00251-012-0646-9. Epub 2012 Aug 18.

PMID:
22903236
25.

Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.

Fujita Y, Suda K, Kimura H, Matsumoto K, Arao T, Nagai T, Saijo N, Yatabe Y, Mitsudomi T, Nishio K.

J Thorac Oncol. 2012 Nov;7(11):1640-4. doi: 10.1097/JTO.0b013e3182653d7f.

26.

Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).

Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y, Sawa T, Ishikura S, Shibata T, Fukuda H, Saijo N, Tamura T; Japan Clinical Oncology Group Lung Cancer Study Group.

Lancet Oncol. 2012 Jul;13(7):671-8. doi: 10.1016/S1470-2045(12)70139-0. Epub 2012 May 22.

PMID:
22622008
27.

[Safety and efficacy of docetaxel in prostate cancer patients: based on the post-marketing surveillance in Japan].

Mera T, Saijo N, Akaza H.

Gan To Kagaku Ryoho. 2012 Apr;39(4):551-62. Japanese.

PMID:
22504677
28.

Present status and problems on molecular targeted therapy of cancer.

Saijo N.

Cancer Res Treat. 2012 Mar;44(1):1-10. doi: 10.4143/crt.2012.44.1.1. Epub 2012 Mar 31.

29.

Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402).

Niho S, Ohe Y, Ishikura S, Atagi S, Yokoyama A, Ichinose Y, Okamoto H, Takeda K, Shibata T, Tamura T, Saijo N, Fukuoka M.

Ann Oncol. 2012 Sep;23(9):2253-8. doi: 10.1093/annonc/mds012. Epub 2012 Feb 22.

PMID:
22357446
30.

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.

Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M; JO19907 Study Group.

Lung Cancer. 2012 Jun;76(3):362-7. doi: 10.1016/j.lungcan.2011.12.005. Epub 2012 Jan 14.

31.

Effect of visuomotor-map uncertainty on visuomotor adaptation.

Saijo N, Gomi H.

J Neurophysiol. 2012 Mar;107(6):1576-85. doi: 10.1152/jn.00204.2011. Epub 2011 Dec 21.

32.

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).

Thongprasert S, Duffield E, Saijo N, Wu YL, Yang JC, Chu DT, Liao M, Chen YM, Kuo HP, Negoro S, Lam KC, Armour A, Magill P, Fukuoka M.

J Thorac Oncol. 2011 Nov;6(11):1872-80. doi: 10.1097/JTO.0b013e31822adaf7.

33.

Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.

Nishio M, Yamanaka T, Matsumoto K, Kimura H, Sakai K, Sakai A, Sone T, Horiike A, Koizumi F, Kasahara K, Ohira T, Ikeda N, Saijo N, Arao T, Nishio K.

J Thorac Oncol. 2011 Nov;6(11):1889-94. doi: 10.1097/JTO.0b013e3182286d41.

34.

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation.

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Br J Cancer. 2011 Oct 25;105(9):1267-72. doi: 10.1038/bjc.2011.395. Epub 2011 Sep 29.

35.

Preface for JCOG review series.

Saijo N.

Jpn J Clin Oncol. 2011 Oct;41(10):1155. doi: 10.1093/jjco/hyr127. No abstract available.

PMID:
21957182
36.

Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.

Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T, Fukuoka M.

J Thorac Oncol. 2012 Jan;7(1):115-21. doi: 10.1097/JTO.0b013e3182307f98.

37.

Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients.

Maekawa K, Hamaguchi T, Saito Y, Tatewaki N, Kurose K, Kaniwa N, Eguchi Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Kamatani N, Ura T, Saito M, Muro K, Fuse N, Yoshino T, Doi T, Otsu A, Saijo N, Sawada J, Okuda H, Matsumura Y.

Drug Metab Pharmacokinet. 2011;26(6):646-58. doi: 10.2133/dmpk.DMPK-11-SC-050. Epub 2011 Aug 16.

38.

Problems involved in the clinical trials for non-small cell lung carcinoma.

Saijo N.

Cancer Treat Rev. 2012 May;38(3):194-202. doi: 10.1016/j.ctrv.2011.06.001. Epub 2011 Jul 19. Review.

PMID:
21775064
39.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

PMID:
21670455
40.

Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.

Saijo N.

Cancer Treat Rev. 2012 Feb;38(1):63-7. doi: 10.1016/j.ctrv.2011.02.004. Epub 2011 Jun 8. Review.

PMID:
21652149
41.

Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients.

Katori N, Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Yomota C, Kawanishi T, Nishimaki-Mogami T, Naito M, Sawada J, Kunitoh H, Nokihara H, Sekine I, Ohe Y, Yoshida T, Matsumura Y, Saijo N, Yamamoto N, Okuda H, Tamura T.

J Pharm Sci. 2011 Oct;100(10):4546-59. doi: 10.1002/jps.22648. Epub 2011 Jun 2.

PMID:
21638284
42.

miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo.

Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, Parissenti A, Duan Z, Voest EE, Zetter BR.

Oncogene. 2011 Oct 27;30(43):4386-98. doi: 10.1038/onc.2011.148. Epub 2011 May 9.

43.

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D.

J Thorac Oncol. 2011 Feb;6(2):244-85. doi: 10.1097/JTO.0b013e318206a221. Review.

44.

Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.

Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, Kudo M, Nishio K.

Mol Cancer Ther. 2011 Jan;10(1):169-77. doi: 10.1158/1535-7163.MCT-10-0544.

45.

Developments for a growing Japanese patient population: facilitating new technologies for future health care.

Kato H, Nishimura T, Ikeda N, Yamada T, Kondo T, Saijo N, Nishio K, Fujimoto J, Nomura M, Oda Y, Lindmark B, Maniwa J, Hibino H, Unno M, Ito T, Sawa Y, Tojo H, Egawa S, Edula G, Lopez M, Wigmore M, Inase N, Yoshizawa Y, Nomura F, Marko-Varga G.

J Proteomics. 2011 May 16;74(6):759-64. doi: 10.1016/j.jprot.2010.12.006. Epub 2010 Dec 22.

PMID:
21184850
46.

Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.

Kudo K, Arao T, Tanaka K, Nagai T, Furuta K, Sakai K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, De Velasco MA, Fujita Y, Saijo N, Kudo M, Nishio K.

Clin Cancer Res. 2011 Mar 15;17(6):1373-81. doi: 10.1158/1078-0432.CCR-09-2755. Epub 2010 Dec 3.

47.

Genetic polymorphisms and haplotypes of por, encoding cytochrome p450 oxidoreductase, in a Japanese population.

Saito Y, Yamamoto N, Katori N, Maekawa K, Fukushima-Uesaka H, Sugimoto D, Kurose K, Sai K, Kaniwa N, Sawada J, Kunitoh H, Ohe Y, Yoshida T, Matsumura Y, Saijo N, Okuda H, Tamura T.

Drug Metab Pharmacokinet. 2011;26(1):107-16. Epub 2010 Nov 12.

48.

Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, Katori N, Saito Y, Ohnami S, Sakamoto H, Sawada J, Saijo N, Yoshida T, Tamura T.

J Thorac Oncol. 2011 Jan;6(1):132-8. doi: 10.1097/JTO.0b013e318200f415.

49.

Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.

Saijo N.

Nat Rev Clin Oncol. 2010 Nov;7(11):618-9. doi: 10.1038/nrclinonc.2010.168. No abstract available.

PMID:
20981125
50.

[Molecular target therapy in cancer].

Saijo N.

Nihon Rinsho. 2010 Oct;68(10):1779-86. Review. Japanese.

PMID:
20954318

Supplemental Content

Support Center